Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amber M Johnson

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of the National Cancer Institute|May 3, 2018
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal CancerJonathan M Loree, Ann M Bailey, Amber M Johnson, et al.
Journal of Medicinal Chemistry|March 15, 2024
Synthetic Approaches to the New Drugs Approved During 2022Scott P France, Erick A Lindsey, Emma L McInturff, et al.
Cancer Research|November 3, 2017
"Personalized Cancer Therapy": A Publicly Available Precision Oncology ResourceKatherine C Kurnit, Ann M Bailey, Jia Zeng, et al.
Journal for Immunotherapy of Cancer|April 22, 2020
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanismsAlexander J Neuwelt, Abigail K Kimball, Amber M Johnson, et al.
Life Science Alliance|May 29, 2019
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLCBonnie L Bullock, Abigail K Kimball, Joanna M Poczobutt, et al.
Cancer Research|November 10, 2017
Complement Activation via a C3a Receptor Pathway Alters CD4<sup>+</sup> T Lymphocytes and Mediates Lung Cancer ProgressionJeff W Kwak, Jennifer Laskowski, Howard Y Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
NPJ Precision Oncology|February 5, 2023
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunityEmily K Kleczko, Trista K Hinz, Teresa T Nguyen, et al.
Frontiers in Oncology|January 23, 2023
Upregulation of complement proteins in lung cancer cells mediates tumor progressionEmily K Kleczko, Joanna M Poczobutt, Andre C Navarro, et al.
Cancer|November 23, 2017
Physician interpretation of genomic test results and treatment selectionLauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of the National Cancer Institute|May 3, 2018
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal CancerJonathan M Loree, Ann M Bailey, Amber M Johnson, et al.
Journal of Medicinal Chemistry|March 15, 2024
Synthetic Approaches to the New Drugs Approved During 2022Scott P France, Erick A Lindsey, Emma L McInturff, et al.
Cancer Research|November 3, 2017
"Personalized Cancer Therapy": A Publicly Available Precision Oncology ResourceKatherine C Kurnit, Ann M Bailey, Jia Zeng, et al.
Journal for Immunotherapy of Cancer|April 22, 2020
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanismsAlexander J Neuwelt, Abigail K Kimball, Amber M Johnson, et al.
Life Science Alliance|May 29, 2019
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLCBonnie L Bullock, Abigail K Kimball, Joanna M Poczobutt, et al.
Cancer Research|November 10, 2017
Complement Activation via a C3a Receptor Pathway Alters CD4<sup>+</sup> T Lymphocytes and Mediates Lung Cancer ProgressionJeff W Kwak, Jennifer Laskowski, Howard Y Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
NPJ Precision Oncology|February 5, 2023
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunityEmily K Kleczko, Trista K Hinz, Teresa T Nguyen, et al.
Frontiers in Oncology|January 23, 2023
Upregulation of complement proteins in lung cancer cells mediates tumor progressionEmily K Kleczko, Joanna M Poczobutt, Andre C Navarro, et al.
Cancer|November 23, 2017
Physician interpretation of genomic test results and treatment selectionLauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Pageof 5